It's saying the overall prevalence in the population from which the study group was drawn was 4.3 per 100k. The study cohort (young men who took SAs during the study time frame) was less than 1000 people, of whom 4 exhibited PSSD. So incidence within the studied group was around 100x the general population prevalence.
sillysaurusx|2 years ago
> Out of the 866 subjects of the study group, four subjects (0.46%) met full case criteria for PSSD (see Fig. 1B). These subjects were 32, 34, 37, and 42 years-old. They used antidepressants with at least a partial serotonergic mechanism (escitalopram, paroxetine, imipramine, or nortriptyline) for 4–8 months before initiating treatment for erectile dysfunction with PDE-5 inhibitors (all used tadalafil and vardenafil, but not sildenafil). They continued to have erectile dysfunction after drug discontinuation as evidenced by 3.6–14.8 months of PDE-5 inhibitor treatment at the end of the study period. The prevalence of PSSD in males of ages 21–49 years of the population of the CHS Tel-Aviv district is 4.3 per 100,000 (4 in 92,476).
4 in 866 is pretty good odds, but everyone has different risk profiles. I’ll be sure to mention it next time Prozac comes up.
amanaplanacanal|2 years ago